Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 126 Parkinson's trials, 10 stopped | 0.84 |
| literature PubMed | 586 Parkinson's papers of 103,017: well-trodden | 0.16 |
| pathways Reactome | 4 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 12586
Sealed predictions
- PC in dopamine neurons, braak-0.33 (p 0.383) → -0.21 (p 0.591)receipt 12593
Swarm cases
receipt 12593: PC in dopamine neurons, braak
- power
- full sample -0.27 (p 0.281, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.239, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.173, n 18). could be the mix.
- skeptic
- leave-one-out range -0.40 to -0.18, sign flips 0; without severely affected donors -0.27 (p 0.281, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.74 (p 4.4e-4, n 18) vs -0.27 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PC in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PC · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.02 p 0.929 (needs p < 1.8e-4)
Receipts
loading the receipts